Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.63 |
| ▸ | CTSS | P25774 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397123 | 1.00 | PPARA (0.63) | PPARACTSSPPARGATMSYK | |
| SCHEMBL18407225 | 0.92 | PPARA (0.69) | PPARACTSSPPARGATMSYK | |
| SCHEMBL31266138 | 0.89 | PPARA (0.62) | PPARACTSSPPARGATMSYK | |
| SCHEMBL27538401 | 0.88 | ATM (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL1132570 | 0.88 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL25467757 | 0.88 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL212796 | 0.88 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL903406 | 0.88 | ATM (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL212797 | 0.88 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL1000339 | 0.87 | PPARA (0.63) | PPARACTSSPPARGATMSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101604-B2 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207997-A1 | Alpha carbolines and uses thereof | CHRM1, CNR1, CXCR1 | PPARA 2626/4885CTSS 1284/4885PPARG 2234/4885 |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | CHRM1, CNR1, CXCR1 | PPARA 2626/4885CTSS 1284/4885PPARG 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.